Just 2 doses of Vitamin D resulted in many benefits (Chronic Kidney Disease)

Created January 2018

Vascular function and cholecalciferol supplementation in CKD: A self-controlled case series

The Journal of Steroid Biochemistry and Molecular Biology, online5 January 2018, https://doi.org/10.1016/j.jsbmb.2018.01.001

Vivek Kumara, , , Ashok Kumar Yadava, Manphool Singhalb, Vinod Kumara, Anupam Lalb, Debasish Banerjeec, d, Krishan Lal Guptaa, Vivekanand Jhaa, e, f

Vitamin D given to 31 individuals having CKD– not a randomized controlled trial cause of CKD was unknown in 50% of subjects. Around 94% were hypertensive | | | | --- | --- | | Week 1 | measurement, 300,000 IU dose | | Week 8 | 300,000 IU dose | | Week 16 | measurement | All of the following measurements had significant increases 1,25(OH)2D 1,25-Dihydroxyvitamin D 25(OH)D 25-Hydroxyvitamin D FMD Endothelium dependent flow mediated dilatation iFGF-23 Intact fibroblast growth factor-23 IL-6 Interleukin-6 iPTH Intact parathormone NMD Endothelium independent nitroglycerine mediated dilatation PWV Pulse wave velocity 1. See also VitaminDWiki * Chronic Kidney Disease mortality is 60 percent less likely if good vitamin D – meta-analysis July 2017 * Standard oral vitamin D is not a good way to supplement if have Chronic Kidney Disease – March 2016 * * Injection category listing has items along with related searches** --- 1. Overview Loading of vitamin D contains the following {include} --- 1. Kidney category starts with {include} 1. Overview Kidney and vitamin D contains the following summary {include} --- The items in both Kidney and Loading Dose categories in VitaminDWiki are:

📄 Download the PDF from VitaminDWiki

image

Highlights

  • Cholecalciferol supplementation in patients with CKD and vitamin D deficiency improved endothelial function (FMD) and vascular stiffness (PWV).

  • NMD also improved which is a novel finding and needs to be explored further.

  • PTH decreased with cholecalciferol supplementation.

  • FGF-23 also decreased with cholecalciferol supplementation unlike previously reported increase with use of activated vitamin D.

Vitamin D deficiency is common and associated with mortality in chronic kidney disease (CKD) patients. Cardiovascular disease (CVD) is the commonest cause of mortality in CKD patients. In a randomized, double blind, placebo controlled trial, we have recently reported favorable effects of vitamin D supplementation on vascular & endothelial function and inflammatory biomarkers in vitamin D deficient patients with non-diabetic stage 3-4 CKD (J Am Soc Nephrol 28: 3100–3108, 2017). Subjects in the placebo group who had still not received vitamin D after completion of the trial received two oral doses 300000 IU of oral cholecalciferol at 8 weeks interval followed by flow mediated dilatation (FMD), pulse wave velocity (PWV), circulating endothelial and inflammatory markers (E-Selectin, vWF, hsCRP and IL-6), 1,25 (OH)2D, iPTH and iFGF-23 assessment at 16 weeks. 31 subjects completed this phase of the study. Last values recorded in the preceding clinical trial were taken as baseline values. Serum 25(OH)D and 1,25(OH)2D increased and FMD significantly improved after cholecalciferol supplementation [mean change in FMD%: 5.8% (95% CI: 4.0-7.5%, p<0.001]. Endothelium independent nitroglycerine mediated dilatation, PWV, iPTH, iFGF-23 and IL-6 also showed favorable changes. The data further cement the findings of beneficial effects of correction of vitamin D deficiency on vascular function.

Tags: Kidney Loading dose